Individual [Axis] All Individuals [Member] Insider Trading Arrangements [Line Items] Trading Arrangement [Axis] Trading Arrangement: All Trading Arrangements [Member] All Trading Arrangements Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Trading Arrangements, by Individual [Table] Name Trading Arrangement, Individual Name Title Trading Arrangement, Individual Title Adoption Date Trading Arrangement Adoption Date Expiration Date Trading Arrangement Expiration Date Arrangement Duration Trading Arrangement Duration Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Accretion of discount and amortization of premium on marketable securities, net Accretion (Amortization) of Discounts and Premiums, Investments Accumulated other comprehensive income (loss) Additional paid-in capital Additional Paid in Capital Current assets of discontinued operations (Note 6) Consolidated Balance Sheets [Abstract] Total assets of discontinued operations Disposal Group, Including Discontinued Operation, Assets Net (loss) income (in dollars per share) Earnings Per Share, Basic Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Cash and cash equivalents Total cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents [Abstract] Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Total cash, cash equivalents and marketable securities Cash and cash equivalents and marketable securities Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents and Marketable Securities [Abstract] Cash decrease upon deconsolidation of subsidiaries Cash Divested from Deconsolidation Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Valuation allowance increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Accrued interest Accounts payable Increase (Decrease) in Accounts Payable, Trade Changes in assets and liabilities, net of effects from acquisition and divestiture: Increase (Decrease) in Operating Capital [Abstract] Accrued expenses Increase (Decrease) in Accrued Liabilities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Number of shares acquired (in shares) Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 695,938,323 and 806,677,954 shares issued and outstanding at March 31, 2025 and 2024, respectively Common Stock, Value, Issued Current taxes [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred taxes [Abstract] Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Deferred Tax Assets (Liabilities) [Abstract] Income Tax Expense (Benefit) [Abstract] Comprehensive (loss) income attributable to Roivant Sciences Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Computers [Member] Computer Equipment [Member] Current tax expense Current Income Tax Expense (Benefit) Total current liabilities Current liabilities Current liabilities: Liabilities, Current [Abstract] Deferred tax benefit Deferred Income Tax Expense (Benefit) Deferred tax assets [Abstract] Deferred Tax Assets, Gross [Abstract] Subtotal Deferred Tax Assets, Gross Capitalized research and development Total deferred tax assets/(liabilities) Deferred Tax Assets, Net Net operating loss Deferred Tax Assets, Operating Loss Carryforwards Other assets Deferred Tax Assets, Other Research tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax liabilities [Abstract] Deferred Tax Liabilities, Gross [Abstract] Other liabilities Deferred Tax Liabilities, Other Deferred revenue Deferred Revenue, Current Liability instruments measured at fair value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Net (loss) income (in dollars per share) Earnings Per Share, Diluted Discontinued Operations Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Cost of revenues Interest expense Disposal Group, Including Discontinued Operation, Interest Expense Disposal Group Name [Domain] Total operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Disposal Group Name [Axis] Income (Loss) from Discontinued Operations, Net of Tax [Abstract] Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Total income tax expense Effective Income Tax Rate Reconciliation, Percent Reconciliation of Income Tax Provision/(Benefit), Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Valuation allowance Income tax expense at Bermuda statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Permanent disallowed IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Other Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Share-based compensation expense Share-Based Payment Arrangement, Expense RSL ESPP [Member] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Share-Based Compensation [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Laboratory and Other Equipment [Member] Ownership percentage Equity Method Investment, Ownership Percentage Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Furniture and Fixtures [Member] Furniture and Fixtures [Member] Change in fair value of investments Gain (Loss) on Investments Loss on extinguishment of debt Loss on extinguishment of debt General and administrative (includes $239,505, $154,873 and $175,019 of share-based compensation expense for the years ended March 31, 2025, 2024 and 2023, respectively) General and administrative expense General and Administrative Expense [Member] General and Administrative Expense [Member] Gross profit Acquired In-Process Research and Development Expenses In Process Research and Development, Policy [Policy Text Block] Consolidated Statements of Operations [Abstract] Summarized Consolidated Financial Information [Abstract] (Loss) income from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent (Loss) income from continuing operations, net of tax (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share (Loss) income from continuing operations, net of tax (in dollars per share) Income (loss) from discontinued operations, net of tax (Income) loss from discontinued operations, net of tax Income (loss) from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income (loss) from discontinued operations, net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Income (loss) from discontinued operations, net of tax (in dollars per share) Income (loss) from discontinued operations before income taxes Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Income tax expense Discontinued Operation, Tax Effect of Discontinued Operation Income Taxes Income Tax Disclosure [Text Block] Interest and penalties related to unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Income Taxes Income Tax, Policy [Policy Text Block] Reconciliation of Income Tax Provision, Amount [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Income tax expense at Bermuda statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Permanent disallowed IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Income taxes paid Income Taxes Paid, Net Investments in Equity Securities Investment, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Total liabilities Liabilities Current liabilities of discontinued operations (Note 6) Noncurrent liabilities of discontinued operations (Note 6) Total liabilities of discontinued operations Disposal Group, Including Discontinued Operation, Liabilities Total liabilities and shareholders' equity Liabilities and Equity Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Marketable securities Marketable Securities, Current Amortized cost Marketable securities [Abstract] Marketable Securities [Abstract] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Money Market Funds [Member] Money market funds Related and Nonrelated Parties [Axis] Cash Flow from Discontinued Operations [Abstract] Net Cash Provided by (Used in) Discontinued Operations [Abstract] Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net (loss) income attributable to Roivant Sciences Ltd. Net Income (Loss) Proceeds from issuance of the Company's common stock under employee stock purchase plan Noncurrent assets Noncurrent liabilities Net operating losses Operating Loss Carryforwards (Loss) income from operations Loss from operations Other comprehensive income (loss): Other Comprehensive Income (Loss), Tax [Abstract] Other current assets Other Assets, Current Other Payments for (Proceeds from) Other Investing Activities Other expense, net Other Nonoperating Income (Expense) Private Placement [Member] Proceeds from sale of subsidiary interests Gross proceeds from sale of common stock Proceeds from issuance of the Company's common shares, net of issuance costs paid Proceeds from Issuance of Common Stock Purchase of equity Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from exercise of the Company's and subsidiary stock options Property and equipment, net Property, Plant and Equipment, Net Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Purchase of marketable securities Payments to Acquire Marketable Securities Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Related and Nonrelated Parties [Domain] Repurchase of the Company's common shares Payments for Repurchase of Common Stock Contributions from issuance of shares Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Sale of Stock [Domain] Purchase price (in dollars per share) Sale price (in dollars per share) Significant Equity Method Investments Equity Method Investments [Table Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Segment Information Significant Segment Expenses Segment Reporting Information [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in shares) Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Non-vested balance, ending (in shares) Non-vested balance, beginning (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Non-vested balance, ending (in dollars per share) Non-vested balance, beginning (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized compensation expense Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Vested (in shares) Service-vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Fair value of CVARs that service-vested Vested (in dollars per share) Service-vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Authorized (in shares) Common shares available for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, beginning balance (in dollars per share) Outstanding, beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options exercisable at September 30, 2023 (in shares) Exercisable, period end (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expected dividend yield Expected stock price volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected risk free interest rate Expected stock price volatility Average of historical and implied volatility Award Type [Domain] All Award Types Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Comprehensive (Loss) Income [Abstract] Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest [Abstract] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Shareholders' equity: Equity, Attributable to Parent [Abstract] Shareholders' Equity Description [Abstract] Class of warrant outstanding (in shares) Shareholders' Equity Equity [Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Sale of Stock [Axis] Supplemental disclosure of cash paid: Supplemental Cash Flow Information [Abstract] Federal research tax credit carryforwards Tax Credit Carryforward, Amount Total current assets Current assets Current assets: Assets, Current [Abstract] Program-specific research and development expenses [Abstract] Research and Development Expense [Abstract] US Treasury Securities [Member] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Investor [Member] Common Stock [Member] Common Shares [Member] Common Stock [Member] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Software [Member] Software Development [Member] Research and development (includes $39,780, $32,400 and $28,669 of share-based compensation expense for the years ended March 31, 2025, 2024 and 2023, respectively) Research and development expense Research and development expenses Cash Cash and cash equivalents Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Reclassified as Assets and Liabilities of Discontinued Operations [Abstract] Assets: Disposal Group, Including Discontinued Operation, Assets [Abstract] Liabilities: Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Unrealized Positions for Held-to-Maturity Securities Total assets Assets Other Current Liabilities [Abstract] Other Liabilities, Current [Abstract] Other current liabilities Total other current liabilities Other Liabilities, Current Other liabilities Other Liabilities, Noncurrent Financial Instruments [Domain] Share-Based Compensation and Other Compensation Plans Share-Based Payment Arrangement [Text Block] Significant Segment Expenses [Abstract] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Statement [Table] Statement [Table] Antidilutive Securities, Name [Domain] Investments measured at fair value Investment Retained investment Aggregate Fair Value Assets Assets [Abstract] Statement [Line Items] Statement [Line Items] Redeemable preferred units Changes in Fair Value of the Level 3 Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in Fair Value of the Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in fair value of liability instruments, included in net income (loss) Change in fair value of debt due to change in subsidiary credit risk Change in fair value of debt due to change in subsidiary credit risk Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Shareholders' Equity [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Class of Stock [Domain] Commitments [Abstract] Long-Term Purchase Commitment [Table] Long-Term Purchase Commitment [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Other assets Other Assets, Noncurrent Operating expenses: Less [Abstract] Total operating expenses Operating Expenses Net (loss) income per common share, basic: Net (loss) income per common share, diluted: Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net (Loss) Income per Common Share [Abstract] Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net (Loss) Income per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Security, Excluded EPS Calculation [Table] Net (Loss) Income per Common Share [Abstract] Earnings Per Share, Diluted, Other Disclosure [Abstract] Other liabilities Increase (Decrease) in Other Operating Liabilities Equity Method Investment [Table] Equity Method Investment [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Class of Stock [Axis] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Property, Plant and Equipment [Line Items] Common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Shareholders' equity attributable to Roivant Sciences Ltd. Equity, Attributable to Parent Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Income tax expense Total income tax expense Income tax expense Income Tax Expense (Benefit) Total liabilities at fair value Equity Components [Axis] Equity Components [Axis] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] (Accumulated Deficit) / Retained Earnings [Member] Retained Earnings [Member] Accumulated Other Comprehensive (Loss) Income [Member] AOCI Attributable to Parent [Member] Equity Component [Domain] Equity Component [Domain] Stock Options [Member] Employee Stock Option [Member] Loss from operations Disposal Group, Including Discontinued Operation, Operating Income (Loss) Forfeited/Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Forfeited/Canceled (in dollars per share) General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Issuance of the Company's common shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Repurchase of the Company's common shares Stock Repurchased and Retired During Period, Value Common shares issued (in shares) Issuance of the Company's common shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Repurchase of the Company's common shares (in shares) Stock Repurchased and Retired During Period, Shares Contingencies Commitments and Contingencies, Policy [Policy Text Block] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Number of Shares [Roll Forward] Weighted-Average Remaining Contractual Term [Abstract] Number of Shares [Roll Forward] Capped Value Appreciation Rights [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Assumptions [Abstract] Net (Loss) Income per Common Share Earnings Per Share [Text Block] Net (loss) income Net income (loss) Net (loss) income Net loss Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Weighted average shares outstanding: (Loss) income from continuing operations, net of tax Net income (loss) from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Amounts attributable to Roivant Sciences Ltd.: Income (loss) from discontinued operations, net of tax Income (loss) from discontinued operations before income taxes attributable to Roivant Sciences Ltd. Loss from discontinued operations before income taxes attributable to noncontrolling interests Depreciation and amortization Comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Beginning balance Ending balance Total shareholders' equity Equity, Including Portion Attributable to Noncontrolling Interest Noncontrolling Interests [Member] Noncontrolling Interest [Member] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Leases [Abstract] Commitments and contingencies (Note 12) Commitments and Contingencies Gain on deconsolidation of subsidiaries Gain on deconsolidation of subsidiaries Gain on deconsolidation of subsidiaries Gain on deconsolidation Deconsolidation of subsidiary Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount Adjustments to reconcile net (loss) income to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Total accrued expenses Accrued Liabilities, Current Compensation-related expenses Employee-related Liabilities, Current Other expenses Other Accrued Liabilities, Current Income tax payable Accrued Expenses [Abstract] Accrued Liabilities, Current [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent (Loss) income before income taxes [Abstract] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract] (Loss) income from continuing operations before income taxes (Loss) income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Increase (Decrease) in Temporary Equity [Roll Forward] Total assets at fair value Assets, Fair Value Disclosure Liabilities at fair value Liabilities, Fair Value Disclosure Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recurring [Member] Fair Value, Recurring [Member] Proceeds from exercise of the Company's warrants Asset Class [Domain] Product revenue, net [Member] Product [Member] Description of Business and Liquidity Business Description and Basis of Presentation [Text Block] Cash, Cash Equivalents and Marketable Securities Ending balance (in shares) Beginning balance (in shares) Shares, Outstanding Balance at end of period Balance at beginning of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Components of Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Income Tax Expense Reconciliation of Income Tax Expense Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] (Loss) Income Before Income Taxes and Related Expense (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Assets and Liabilities are Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Cash, Cash Equivalents, and Marketable Securities Cash, Cash Equivalents and Investments [Table Text Block] Commitments and Contingencies [Abstract] Income Taxes [Abstract] Fair Value Measurements [Abstract] Activity for RSUs Activity of PSU's Performance Condition Share-Based Compensation Arrangements by Share-Based Payment Award, Performance-Based Units, Vested and Expected to Vest [Table Text Block] Schedule of Fair Value Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-Based Compensation and Other Compensation Plans [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Restricted Stock Units [Member] Restricted Common Stock (Non-vested) [Member] Assets: [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Calculation Using Significant Unobservable Inputs Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Liabilities: [Abstract] Recurring Fair Value Measurements [Abstract] Research and Development Expense [Member] Summary of Significant Accounting Policies [Abstract] Equity Method Investments [Abstract] Discontinued Operations [Abstract] Segment Information [Abstract] Other Other Noncash Income (Expense) Certain Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Unrealized (Gain) Loss on Investment Unrealized Gain (Loss) on Investments Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Lower estimated volatility Higher estimated volatility Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted Average Grant Date Fair Value [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unrecognized compensation expense Share price (in dollars per share) Stock price (in dollars per share) Financial Instrument [Axis] Beginning balance Ending balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Average Exercise Price [Roll Forward] Granted (in dollars per share) Exercised (in dollars per share) Performance Restricted Stock Units [Member] Performance Restricted Stock Units [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Award Type [Axis] Subsequent Event [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Recently Adopted/ Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Estimated useful lives Property, Plant and Equipment, Useful Life Outstanding, weighted-average remaining contractual term Exercisable, weighted-average remaining contractual term Expected term, in years Performance of grant date Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Remaining weighted-average service period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of operating segments Number of Operating Segments Number of reporting segments Number of Reportable Segments Purchase commitment to be paid during fiscal year ending March 31, 2026 Purchase commitment to be paid during fiscal year ending March 31, 2028 Purchase commitment to be paid during fiscal year ending March 31, 2029 Purchase commitment to be paid during fiscal year ending March 31, 2030 Federal research tax credit carryforwards expiration date Tax Credit Carryforward, Expiration Date Changes in fair value of investment in Datavant, included in net (income) loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Depreciation and amortization Depreciation and Amortization, Discontinued Operations Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Issuance of subsidiary preferred shares Net operating losses expiration date Operating Loss Carryforwards, Expiration Date Grant date fair value of options vested Fair value of stock options vested Accounts payable Accrued expenses Vesting [Axis] Vesting [Domain] Other Current Liabilities Percentage of vesting rights Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Award Date [Axis] Award Date [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Gross unrealized losses Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss Gross unrealized gains Property and equipment, net Intangible assets, net First Tranche [Member] Share-Based Payment Arrangement, Tranche One [Member] Second Tranche [Member] Tranche Two [Member] Third Tranche [Member] Noncurrent assets of discontinued operations (Note 6) Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Disposal Group Classification [Axis] Disposal Group Classification [Domain] Discontinued Operations, Disposed of by Sale [Member] Discontinued Operations, Disposed of by Sale [Member] Amounts reclassified from accumulated other comprehensive income (loss) Amounts reclassified from accumulated other comprehensive (loss) income Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Operating Lease Cost [Abstract] Operating lease cost Operating Lease, Cost Short-term lease cost Short-Term Lease, Cost Variable lease cost Variable Lease, Cost Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Maturities of Operating Lease Liabilities [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Revenue Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lease Agreement [Abstract] Cash, Cash Equivalents, and Restricted Cash [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Restricted cash (included in "Other current assets") Restricted Cash, Current Restricted cash (included in "Other assets") Effect of exchange rate changes on cash, cash equivalents and restricted cash Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash paid for operating lease liabilities Operating Lease, Payments Payments on principal portion of finance lease obligations Finance Lease, Principal Payments Operating lease right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease payments Lessee, Operating Lease, Liability, to be Paid Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five 2026 Lessee, Operating Lease, Liability, to be Paid, Year One 2030 Lessee, Operating Lease, Liability, to be Paid, Year Five 2029 Lessee, Operating Lease, Liability, to be Paid, Year Four 2028 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Lessee, Operating Lease, Liability, to be Paid, Year Two Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Total lease liabilities Operating lease liability Operating Lease, Liability Operating lease liabilities Operating Lease, Liability, Current Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Components of Operating Lease Expense Lease, Cost [Table Text Block] Leases Lessee, Leases [Policy Text Block] Leases Lessee, Operating Leases [Text Block] Measurement Input Type [Axis] Discount Rate [Member] Term (in years) [Member] Measurement Input, Expected Term [Member] Volatility [Member] Measurement Input, Price Volatility [Member] Risk-free Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input Type [Domain] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Lease renewal term Tax deficiencies (excess tax benefits) from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Tax deficiencies (excess tax benefits) from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Marketable Securities [Table] Marketable Securities [Line Items] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Warrants expiration period Warrants and Rights Outstanding, Term Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Domain] Non-cash lease expense Fair value Operating lease liabilities Increase (Decrease) in Operating Lease Liability Asset Acquisition [Abstract] Asset Acquisition [Abstract] Asset Acquisition [Table] Asset Acquisition [Line Items] Fair value of consideration transferred Asset Acquisition, Consideration Transferred Derivative Liability, Statement of Financial Position [Extensible Enumeration] Title and Position [Domain] Investment, Name [Domain] Independent Directors [Member] Chief Executive Officer [Member] Chief Executive Officer [Member] Scenario [Domain] Forecast [Member] Forecast [Member] Scenario [Axis] Investment, Name [Axis] Geographical [Domain] Geographical [Domain] Geographical [Axis] Geographical [Axis] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Weighted Average [Member] Title and Position [Axis] Common stock repurchase authorized amount Consolidated Entities [Axis] Consolidated Entities [Domain] Product and Service [Domain] Product and Service [Axis] Bermuda [Member] BERMUDA Switzerland [Member] SWITZERLAND United Kingdom [Member] UNITED KINGDOM United States [Member] UNITED STATES Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Cover [Abstract] Document Type Document Annual Report Document Transition Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Firm ID Auditor Location The fair value of liability instruments measured at fair value. Liability Instruments Measured At Fair Value [Member] Liability Instruments Measured at Fair Value [Member] Fair value of other liability instruments measured at fair value. Other Liability Instruments Measured At Fair Value Other liability instruments The fair value of earn-out shares issued. Earnout Shares [Member] Earn-Out Shares [Member] The name of related party. Datavant Holdings, Inc [Member] Datavant [Member] The name of related party. Arbutus Biopharma Corporation [Member] Arbutus Biopharma Corporation [Member] Noncontrolling interests that are mandatorily redeemable upon a certain date or event occurring. Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest [Member] Stock issued during the period value, net of issuance costs. Stock Issued During Period, Value, Net Issuance Costs Issuance of the Company's common shares, net of issuance costs The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the disposition of subsidiary. Noncontrolling Interest, Increase Decrease from Disposition Disposition of Telavant Aggregate change in value issuance of the company's common share related to settlement of warrants value. Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Value Issuance of the Company's common shares related to settlement of warrants The amount of common shares issued related to settlement of transaction consideration. Stock Issued During Period, Value, Common Shares Related to Settlement of Transaction Consideration Issuance of the Company's common shares related to settlement of transaction consideration Dividend declared by subsidiary. Dividend Declared by Subsidiary Dividend declared by subsidiary The number of common shares issued related to settlement of transaction consideration. Stock Issued During Period, Shares, Common Shares Related to Settlement of Transaction Consideration Issuance of the Company's common shares related to settlement of transaction consideration (in shares) The number of shares issued in connection with equity incentive plans and tax withholding payments. Stock Issued During Period, Shares, in Connection with Equity Incentive Plans and Tax Withholding Payments Issuance of common shares in connection with equity incentive plans and tax withholding payments (in shares) Number of stock issued during the period net of issuance costs. Stock Issued During Period, Shares, Net Issuance Costs Issuance of the Company's common shares, net of issuance costs (in shares) Number of shares issued common share related to settlement of warrants shares. Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Shares Issuance of the Company's common shares related to settlement of warrants (in shares) The number of shares issued in connection with equity incentive plans net of forfeitures and tax withholding payments. Stock Issued During Period, Shares, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares) The amount net common shares issued of subsidiary to the company, net of issuance costs. Net Issuance Of Subsidiary Common Shares Value Issuance of subsidiary common shares, net The value of stock issued in connection with equity incentive plans net of forfeitures and tax withholding payments. Stock Issued During Period, Value, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments Amount of noncontrolling interest from sale of interests in subsidiary. Noncontrolling Interest, Sale of Interests in Subsidiary Sale of interests in subsidiary The value of stock issued in connection with equity incentive plans and tax withholding payments. Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments Issuance of common shares in connection with equity incentive plans and tax withholding payments The amount net common shares issued of subsidiary to the company and cash contributions to majority-owned subsidiaries. Issuance of Subsidiary Common Shares to the Company and Capital Contributions to Subsidiaries Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries The amount of the increase in or (reduction or elimination) during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest. Noncontrolling Interest, Increase Decrease from Deconsolidation Deconsolidation of subsidiaries Amount of increase to additional paid-in capital (APIC) and Noncontrolling Interest for recognition of cost for award under share-based payment arrangement. APIC and Noncontrolling Interest, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation The number of stock issuance of common shares and other consideration for acquisition during the period. Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Shares Issuance of the Company's common shares and other consideration for an acquisition (in shares) Number of common shares issuance of subsidiary to the Company. Issuance of Subsidiary Common Shares to the Company, Shares Issuance of subsidiary common shares, net (in shares) The amount of subsidiary stock issued as a result of stock options exercised. Stock Issued During Period, Value, Subsidiary, Stock Options Exercised Subsidiary stock options exercised Value of stock issuance of common shares and other consideration for acquisition. Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Value Issuance of the Company's common shares and other consideration for an acquisition Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. Samsung Biologics Co., Ltd. [Member] Samsung [Member] Name of the entity. Bayer AG (Pulmovant, Inc.) [Member] Bayer AG (Pulmovant, Inc.) [Member] Name of the entity. HanAll Biopharma Co., Ltd. (Immunovant) [Member] The maximum potential future milestone payment pursuant to certain key asset acquisition and license agreements. Maximum Potential Future Milestone Payments Potential material future milestone payments The remaining minimum amount of purchase commitment related to agreements. Remaining Minimum Purchase Commitment Related to Agreement Remaining minimum purchase commitment related to agreement The period to purchase additional batches of batoclimab, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period to Purchase Additional Batches of Batoclimab Period to purchase additional batches of batoclimab Amount of liability instruments measured at fair value. Liability Instruments Measured at Fair Value Liability instruments measured at fair value Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the lease liabilities. Deferred Tax Assets, Lease Liabilities Lease liabilities Amount of deferred tax liability attributable to taxable temporary differences from right of use assets. Deferred Tax Liabilities, Right-of-use Assets Right-of-use assets Amount of deferred tax liability attributable to taxable temporary differences from depreciation. Deferred Tax Liabilities, Depreciation Depreciation Disclosure of information about income taxes. Income Taxes [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Income Taxes [Line Items] It includes the greater china and united kingdom activity. Other [Member] Other [Member] Tabular disclosure of financial information for equity method investments. Equity Method Investment, Summarized Financial Information [Table Text Block] Consolidated Financial Information The name of combined merged entity. Ciox Parent [Member] Datavant Merger [Member] For all equity method investments in an unrealized loss (gain) position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of equity method investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value). Schedule of Unrealized Loss (Gain) on Equity Method Investments [Table Text Block] Unrealized Losses (Gains) on Significant Equity Method Investments Amount of gain (loss) on fair value of liability instruments. Gain (Loss) on Fair Value of Liability Instruments Change in fair value of liability instruments Interest income on nonoperating activities. Interest Income Interest income Amount of acquired in-process research and development expense. Acquired in Process Research and Development Expense Acquired in-process research and development The total amount of operating cost and expense. Operating Costs Cost of revenues Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Gain (Loss) on Sale of Assets Gain on sale of Telavant net assets Gain on sale of Telavant net assets Income Tax operating losses [Abstract] Income Tax Operating Losses [Abstract] Percentage of future taxable income for tax years and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. Annual Net Operating Loss Utilization Limitation Percentage Annual net operating loss utilization limitation percentage United States and Canada. United States And Canada [Member] States in U.S and Canada [Member] Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax-effect of changes in the fair value of investments and loss from equity method investment. Effective Income Tax Rate Reconciliation, Changes in Fair Value of Investments and Loss from Equity Method Investment, Percent Tax effect of changes in the fair value of investments and loss from equity method investments Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to significant shareholding exemption. Effective Income Tax Rate Reconciliation, Significant shareholding exemption, Percent Substantial shareholding exemption Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other permanent adjustments Effective Income Tax Rate Reconciliation, Other Permanent Adjustments, Percent Other permanent adjustments Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax-effect of changes in the fair value of investments and loss from equity method investment. Effective Income Tax Rate Reconciliation, Changes in Fair Value of Investments and Loss from Equity Method Investment Tax effect of changes in the fair value of investments and loss from equity method investments Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to reversal of certain deferred tax assets. Effective Income Tax Rate Reconciliation, Reversal of Certain Deferred Tax Assets, Percent Reversal of certain deferred tax assets Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to reversal of certain deferred tax assets. Effective Income Tax Rate Reconciliation, Reversal of Certain Deferred Tax Assets, Amount Reversal of certain deferred tax assets Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other permanent adjustments. Effective Income Tax Rate Reconciliation, Other Permanent Adjustments, Amount Other permanent adjustments Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to substantial shareholding exemption. Effective Income Tax Rate Reconciliation, Substantial Shareholding Exemption, Amount Substantial shareholding exemption The name of related party. Sumitomo Pharma Co. Ltd. [Member] Sumitomo Pharma Co. Ltd. [Member] Name of subsidiary. Immunovant, Inc. [Member] Immunovant, Inc. [Member] Public offering in which the Common Stock is offered and sold on a firm commitment basis through one or more underwriters. Underwritten Public Offering [Member] Underwritten Public Offering [Member] Offering of "at-the-market" shares as per equity distribution agreement. Equity Offerings at the Market [Member] At-the-Market Equity Offering Program[Member] Roivant participation of Immunovant Stock offering [Member] Roivant Participation of Immunovant Stock offering [Member] The common shares sold by RSL. Sold by RSL [Member] Sold by RSL [Member] Cytovant [Member] Cytovant [Member] Cytovant [Member] An affiliate with whom the entity entered into a sales agreement. Cowen and Company, LLC [Member] Cowen [Member] A program to buyback its own share. Stock Repurchase Program [Member] Stock Repurchase Program [Member] Number of new stock purchased during the period. Stock Purchased During Period by Entity, Shares Common shares purchased by RSL (in shares) The net cash inflow from the additional capital contribution to the entity. Net Proceeds from Issuance of Common Stock Net proceeds from sale of common stock The common shares aggregate offering price authorized remaining capacity to issue under equity offering program. Common Shares Aggregate Offering Price Authorized, Remaining Capacity Available Common shares aggregate offering price authorized, remaining capacity available This represents the number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Number of Stock Repurchased During Period, Shares Number of shares repurchased (in shares) The percentage ownership of a subsidiary. Ownership of Subsidiary Percentage Ownership of subsidiary The common shares aggregate offering price authorized to issue under equity offering program. Common Shares Offering Price Authorized Common shares aggregate offering price authorized This represent the aggregate equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Aggregate amount for Stock Repurchased During Period, Value Aggregate purchase price Number of additional shares of common stock option to purchase. Option to Purchase Additional Shares of Common Stock Option purchase additional shares of common stock (in shares) Stock sold during period by selling shareholders. Stock Sold During Period by Selling Shareholders Stock sold during period by selling shareholders (in shares) Number of shares of stock issued and sold upon exercise of the underwriters option. Stock Issued and Sold Upon Exercise of the Underwriters Option Common stock, shares issued upon exercise of underwriter's options (in shares) The common shares sold by selling shareholders. Sold by Selling Shareholders [Member] Sold by Selling Shareholders [Member] Amount of investment in marketable security, US Government Treasury Securities classified as current. Marketable Securities, US Government Treasury Securities Current U.S. Treasury securities Amount of cash inflow from the sale of Top-Up shares attributable to discontinued operations. Proceeds from Sale of Top-Up Shares, Discontinued Operations Proceeds from sale of Myovant Top-Up Shares Name of related party. Myovant Sciences Ltd. [Member] Myovant Sciences Ltd. [Member] RSL [Member] Amount of cash outflow from gain (loss) on recovery of contingent consideration attributable to discontinued operations. Gain (Loss) on Recovery of Contingent Consideration, Discontinued Operations Gain on recovery of contingent consideration Myovant Transaction [Abstract] Myovant Transaction [Abstract] The maximum number of shares of Common Stock that such holder of Applicable Shares is entitled to purchase pursuant to an agreement. Number of Top-Up shares received Number of Top-Up shares received (in shares) Number of Vants in which the entity has ownership interest. Number of Vants Number of Vants Amount of lease cost recognized by lessee for operating lease contract. Operating Lease, Costs Total operating lease cost Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Lessee, Operating Lease, Disclosure [Table Text Block] Operating Lease Right-of-use Assets and Lease Liabilities Property And Equipments [Abstract] Property and Equipment [Abstract] Tabular disclosure of useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Property and Equipment, Estimated Useful Life [Table Text Block] Estimated Useful Life Amount of tenant improvement allowance adjustment for operating lease. Lessee Operating Lease Liability Tenant Improvement Allowance Less: tenant improvement allowance Amount of present value adjustment for operating lease. Operating Lease Liability Present Value Adjustments Less: present value adjustment Subsidiaries lease agreement for office space. Roivant Sciences Inc Lease Agreement [Member] RSI Lease Agreement [Member] Person with designation of president and chief operating officer. President and Chief Operating Officer [Member] President and Chief Operating Officer [Member] Person with designation of president and chief investment officer. President and Chief Investment Officer [Member] President and Chief Investment Officer [Member] Intrinsic value of grants award under share-based payment arrangement. Excludes share and unit options. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Granted Aggregate grant date fair value Period of trailing trading days, weighted average trading price used to calculate performance Condition of PSUs in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period of Trailing Trading Days, Weighted Average Trading Price used to Calculate Performance Condition of PSUs Term of trailing trading days, weighted average price use to calculate performance condition of PSUs The number of tranches available for vesting of under 2024 Senior Executive Compensation Program. Number of Vesting Tranches Number of tranches available for vesting The PSUs holding period before such common shares may be sold by the executive (subject to certain exceptions) in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. PSUs Holding Period Before Common Shares May be Sold by Executive PSUs holding period before common shares may be sold by executive Represents the Chief Executive Officer and the President and Chief Investment Officer. CEO and CIO [Member] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of PSUs Valuation Assumptions. Schedule Of Share Based Payment Award PS Us Valuation Assumptions [Table Text Block] Schedule of Fair Value Assumptions Schedule Of Share Based Compensation Stock Options And Performance Options Activity. Schedule Of Share Based Compensation Stock Options And Performance Options Activity [Table Text Block] Activity for Stock Options and Performance Stock Options Tabular disclosure of share based compensation equity incentive awards approved activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. Schedule Of Share Based Compensation Equity Incentive Awards Approved [Table Text Block] Summary of Long-Term Equity Incentive Awards Approved Tabular disclosure of cash retention awards. Schedule Of Cash Retention Awards [Table Text Block] One-time Cash Retention Awards Tabular disclosure of the number and weighted-average grant date fair value for performance stock units that were outstanding at the beginning and end of the year, and the number of performance stock units that were granted, vested, or forfeited during the year. Share-Based Payment Arrangement, Performance Stock Unit, Activity [Table Text Block] Activity for PSUs Tabular disclosure share based payment arrangement fair value of vested stock option and performance option. Schedule of Share Based Payment Arrangement Fair Value of Vested Stock Option and Performance Option [Table Text Block] Summary of Fair Value of Vested Stock Option Tabular disclosure of the capped value appreciation rights stock units activity. Schedule of Capped Value Appreciation Rights Stock Units Activity [Table Text Block] Activity for Capped Value Appreciation Rights Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target. Stock Options and Performance Stock Options [Member] Stock Options and Performance Stock Options [Member] The intrinsic value of options exercised during the period. Intrinsic Value of Options Exercised Intrinsic value of options exercised Weighted average grant-date fair value of options granted. Sharebased Compensation Arrangement by Sharebased Payment Award, Options, Granted, Weighted Average Grant Date Fair Value Weighted-average grant date fair value per share of stock options granted (in dollars per share) The company approved a special one-time cash retention bonus award to its employees. Cash Bonus Program [Member] Cash Bonus Program [Member] Cash Bonus Program [Abstract] Compensation related to one time cash retention bonus award to employees. Compensation Related Expense Compensation-related expenses The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "RSL 2021 EIP"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the "RSL Equity Plans"). Roivant Sciences Ltd Equity Plans [Member] RSL Equity Plans [Member] The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the "RSL 2021 EIP"). Roivant Sciences Ltd 2021 Equity Incentive Plan [Member] RSL 2021 EIP [Member] Equity incentive plan term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Equity Incentive Plan Term Equity incentive plan term The number of equity incentive plans for the company during the period. Number of Equity Incentive Plans Number of equity incentive plans Aggregate Intrinsic Value [Abstract] Employee Stock Purchase Plan [Abstract] Employee Stock Purchase Plan [Abstract] Maximum amount of annual contribution an eligible employee can made under the employee stock purchase plan. Maximum Amount of Annual Contribution Maximum amount of contribution of base salary Percentage of stock purchase price equal to lower of closing price on first and last trading day of the offering period in which the eligible employees can buy shares under the Employee stock purchase plan. Percentage of Stock Purchase Price Equal to Lower of Closing Price Percentage of stock purchase price equal to lower of closing price under ESPP Percentage of maximum contribution of base salary an eligible employee can made under the employee stock purchase plan. Percentage of Maximum Contribution of Base Salary Percentage of maximum contribution of base salary Description of Business and Liquidity [Abstract] Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd. Subsidiary Equity Incentive Plans [Member] Subsidiary Equity Incentive Plans [Abstract] Subsidiary Equity Incentive Plans [Abstract] Liquidity [Abstract] Liquidity [Abstract] Amount of cash payment received for sale of assets. Cash Payment Received For Sale Of Assets Cash payment received for sale of assets Description of Business [Abstract] Description of Business [Abstract] Name of the entity. Telavant Holdings, Inc [Member] Telavant Holdings, Inc [Member] Telavant Holdings, Inc. [Member] Recent Transactions and Developments [Abstract] The entire disclosure for recent transactions and development. Recent Transactions and Developments [Text Block] Recent Transactions and Developments Tabular disclosure of information related to the calculation of the gain on sale of assets. Schedule of Gain on Sale of Assets Calculation [Table Text Block] Calculation of Gain a wholly-owned subsidiary of the Company, in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment. Pulmovant [Member] The name of entity owned or controlled subsidiary. ProteoVant Sciences, Inc [Member] Proteovant [Member] Name of the entity. SK, Inc. [Member] SK Biopharmaceuticals Co., Ltd. ("SK Bio"), a subsidiary of SK Inc. SK Biopharmaceuticals Co Ltd [Member] Preferred financing in exchange for shares of VantAI's Series Spin Preferred Stock VantAI Preferred Financing [Member] Amount of asset acquisition research and development expense in-process. Asset Acquisition, Research and Development Expense in Process Acquired in process research and development expense Amount of milestone payment payable. Milestone Payment Payable Milestone payment payable The cash outflow associated with the upfront cash payment during the period. Upfront Cash Payment Upfront Cash Payment Deconsolidation of Subsidiaries [Abstract] Measurement input using rate at which historical price of security will increase (decrease) for given set of returns. Measurement Input, Historical Volatility [Member] Historical Volatility [Member] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Fair value asset, measurement input. Fair Value Asset, Measurement Input Investment in equity securities, measurement input The fair value measurement input for Earn-out shares. Fair Value Earnout Shares Measurement Input Earn-out share, measurement input Name of business transaction. Roche Transaction [Member] Disposal Group [Abstract] Telavant Disposition [Abstract] Disposal Groups, Including Discontinued Operations, Calculation of Gain [Abstract] Calculation of Gain [Abstract] Amount classified as net assets (liabilities) attributable to disposal group held for sale. Disposal Group, Net Assets (Liabilities) Net liabilities sold Amount classified as assets attributable to disposal group held for sale. Disposal Group, Assets Assets sold Amount classified as liabilities attributable to disposal group held for sale. Disposal Group, Liabilities Liabilities transferred Disposal Group, Consideration [Abstract] Consideration [Abstract] The carrying amount of noncontrolling interest derecognized attributable to disposal group held for sale. Disposal Group, Noncontrolling Interest, Derecognized Value Carrying amount of noncontrolling interest derecognized The future milestone to be received from sale of assets. Future Milestone to be Received from Sale of Assets Consideration to be received from milestone Amount of consideration received for sale of assets. Consideration received for sale of Assets Total consideration Amount of before tax of income (loss) from a disposal group. Income (Loss) from Disposal Group, before Income Tax Pretax loss Name of the entity. Pfizer [Member] Amount of upfront cash payment received for sale of assets. Upfront Cash Payment Received for Sale of Assets Upfront cash payment Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract] The entire disclosure of earn-out shares, public warrants and private placement warrants. Earn-Out Shares, Public Warrants and Private Placement Warrants [Text Block] Earn-Out Shares, Public Warrants and Private Placement Warrants Schedule for earn-out shares, public warrants and private placement warrants. Earn-Out Shares, Public Warrants and Private Placement Warrants [Table] Name of the sponsor company. Patient Square Capital Limited Liability Company [Member] MAAC Sponsor [Member] Security that gives the holder the right to purchase one share of common stock at a specific exercise price. Private Placement Warrants [Member] Private Placement Warrants [Member] In finance, a warrant is a security that entitles the holder to buy or sell stock, typically the stock of the issuing company, at a fixed price called the exercise price. Public Warrants [Member] Public Warrants [Member] Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price. Public Warrants and Private Placement Warrants [Member] Public and Private Warrants [Member] The percentage of earn-out shares. Ten Percent Earn-Out Shares [Member] 10 % Earn-Out [Member] The percentage of earnout shares. Twenty Percent Earn-Out Shares [Member] 20% Earn-Out [Member] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Earn-Out Shares, Public Warrants and Private Placement Warrants [Line Items] Public Warrants and Private Placement Warrants [Abstract] Public Warrants and Private Placement Warrants [Abstract] Number of shares unexercised of warrant redeemed during the period. Class of Warrant or Right Unexercised Price of Warrants Unexercised public warrants (in shares) Number of cashless public warrants exercised during the period. Cashless Public Warrant Exercised Cashless warrant exercised (in shares) Number of common shares issued to surrendering holder per warrant during the period. Stock Issued During Period Number of Shares Issued to Surrendering Holder Per Warrant Number of common shares issued to surrendering holder per warrant (in shares) Number of trading days for common stock price to exceed threshold, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days Number of trading days The exercise price per Common Share on a cashless basis to exercise warrants. Exercise Price Cashless exercise price (in dollars per share) The exercise price per common share on a cash basis to exercise warrants. Cash Exercise Price Cash exercise price (in dollars per share) Aggregate number of shares exchanged during the period. Stock Issued During Period Shares Cash Warrant Exercises Aggregate value of shares exchanged (in shares) Earn-Out Shares [Abstract] Earn-Out Shares [Abstract] The collective percentage of earn-out shares. Percentage of Earn-Out Shares Percentage of earn-out shares The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days to be used to Meet Earn-Out Share Price Threshold Number of trading days to meet earn-out price threshold Period after the completion of a business combination when warrants will become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period to Exercise Warrants After Business Combination Period to exercise warrants after business combination Number of earn-out shares vested during period. Number of Earn-Out Shares Vested Number of earn-out shares vested (in shares) Number of Public warrants cash exercised during the period. Public Warrant Cash Exercised Warrant exercised (in shares) Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days Allowed to Calculate Earn-Out Share Price Threshold Trading day period for earn-out shares Aggregate number of shares exchanged on a cashless basis during the period. Stock Issued During Period Shares Cashless Warrant Exercises Aggregate value of shares exchanged on a cashless basis (in shares) The share price of earn-out share. Earn-Out Share Price Earn-out share price (in dollars per share) Redemption price per share or per unit of warrants or rights outstanding. Class of Warrant or Right Redemption Price Redemption price (in dollars per share) Represents the license, milestone, and other revenue. License, Milestone and Other Revenue [Member] License, milestone and other revenue [Member] Amount of gain (loss) on sale of interest in subsidiaries. Gain (Loss) on Sale of Interest in Subsidiary Gain on sale of subsidiary interests Amount of accumulated other comprehensive income (loss) attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Income (Loss) Loss on sale of business, accumulated other comprehensive loss Amount of revenue from contract with customer excluding assessed tax attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Revenue from Contract with Customer Excluding Assessed Tax Revenue, net Amount of other (income) expense, net attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group Including Discontinued Operation Other (Income) Expense, Net Other income, net Disposal Group Including Discontinued Operating Expenses [Abstract] Operating expenses: Amount of research And development expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group Including Discontinued Operation Research and Development Expense Research and development Non-Cash Operating and Investing from Discontinued Operations [Abstract] Non-Cash Operating and Investing from Discontinued Operations [Abstract] Amount of noncash change in the fair value of debt related to discontinued operations Change in Fair Value of Debt, Discontinued Operations Change in fair value of debt Amount of change in fair value of debt attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group, Including Discontinued Operation, Change in Fair Value of Debt Change in fair value of debt Amount of noncash expense for share-based payment arrangement attributable to discontinued operations. Share-Based Compensation, Discontinued Operations Share-based compensation Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group Including Discontinued Operation Selling, General and Administrative Expense Selling, general and administrative Disposal Group Discontinued Operation Disposal Disclosures [Abstract] Disposal Group Discontinued Operation Disposal Disclosures [Abstract] Amount of consideration receivable under the liquidation preference of preference shares pursuant to merger agreement. Disposal Group Including Discontinued Operation Liquidation Consideration Receivable Consideration receivable under liquidation preference Amount of receivable for the sale or disposal of assets and liabilities, including discontinued operation. Receivable from Sale of Discontinued Operations Receivable from sale of discontinued operations Amount of Milestone Receivable for the disposal of assets and liabilities, including discontinued operation. Milestone Receivable from Sale of Discontinued Operations Amount of Milestone Received for the disposal of assets and liabilities, including discontinued operation. Milestone Received From Sale Of Discontinued Operations Milestone received from sale of discontinued operations Percentage of liquidation preference receivable on preference shares pursuant to merger agreement. Disposal Group Including Discontinued Operations Percentage of Liquidation Preference Receivable Percentage of liquidation preference receivable The percentage of net sales for future royalty payments Percentage of Net Sales for Future Royalty Payments Percentage of annual net sales Amount of Sale milestone receivable for the disposal of assets and liabilities, including discontinued operation. Sale Milestone Receivable from Sale of Discontinued Operations Amount of net sales attributable to disposal group, including, but not limited to, discontinued operation. Disposal Group Including Discontinued Operation, Net Sales Net sales Name of the acquiree. Dermavant [Member] Dermavant [Member] Amount classified as current and non-current other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. Disposal Group, Including Discontinued Operation, Other Liabilities, Current and Noncurrent Other liabilities Amount classified as other current and non-current assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. Disposal Group, Including Discontinued Operation, Other Assets, Current and Noncurrent Other assets Amount classified as operating lease right-of-use assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. Disposal Group, Including Discontinued Operation, Property, Operating Lease Right-of-Use Assets, Noncurrent Operating lease right-of-use assets Amount classified as long-term debt attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. Disposal Group Including Discontinued Operation Operating Long-term Debt Noncurrent Long-term debt Amount classified as current and non-current operating lease liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. Disposal Group Including Discontinued Operation Operating Lease Liabilities Current and Noncurrent Operating lease liabilities The Cash inflow resulting from the sale of discontinued operation. Proceeds from Sale of Discontinued Operation Cash received Represents Research and development personnel related expenses. Personnel Related Expenses [Member] Represents other research and development related expenses. Other Research and Development Expenses [Member] Represents General and Administrative Personnel Related Expenses. Personnel Related Expenses, General and Administrative [Member] Represents Other General and Administrative Expenses. Other General and Administrative Expenses [Member] Rheumatology diseases is a chronic progressive autoimmune disease that causes inflammation in the joints and surrounding tissues. Anti-FcRn Franchise-Rheumatology Diseases [Member] Anti-FcRn Franchise-Rheumatology Diseases [Member] Dermatology diseases is a rare, chronic skin disease characterized by skin-specific disease activity, inflammation and eventually damage. Anti-FcRn Franchise-Dermatology Diseases [Member] Anti-FcRn Franchise-Dermatology Diseases [Member] Mosliciguat it is an inhaled soluble guanylate cyclase activator developed by Bayer for pulmonary arterial hypertension. Mosliciguat [Member] Mosliciguat [Member] Endocrine disease is an autoimmune disease that affects the thyroid gland. Anti-FcRn Franchise-Endocrine Diseases [Member] Anti-FcRn Franchise-Endocrine Diseases [Member] Neurological disorders represent a complex array of medical conditions that fundamentally disrupt the functioning of the nervous system. These disorders affect the brain, spinal cord, and nerve networks, presenting unique diagnosis, treatment, and patient care challenges. Anti-FcRn Franchise-Neurological Diseases [Member] Anti-FcRn Franchise-Neurological Diseases [Member] Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other clinical and nonclinical Anti-FcRn Franchise-Other Clinical and Nonclinical [Member] Anti-FcRn Franchise-Other Clinical and Nonclinical [Member] Brepocitinib it represent selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Brepocitinib [Member] Brepocitinib [Member] Research and development expenses classified as other development and discovery programs. Other Development and Discovery Programs [Member] Other Development and Discovery Programs [Member] President and chief operating officer of the company. Eric Venker [Member] Eric Venker [Member] Sale [Member] Payment made during the period for achieving the milestone or milestones. Milestone Payments Milestone payments The cash inflow associated with the aggregate amount received by the entity through subsidiary debt financings, net during the period. Proceeds from Subsidiary Debt Financings, Net Proceeds from subsidiary debt financings, net of financing costs paid Payments of Taxes for the Repurchase of Equity. Payments of Taxes for the Repurchase of Equity Taxes paid related to net settlement of equity awards The net cash inflows from issuance of subsidiary common shares, net of issuance costs paid. Proceeds from Issuance of Subsidiary Common Shares, Net Proceeds from issuance of subsidiary common shares, net of issuance costs paid The cash outflow associated with payment for offering and loan costs during the period. Payment for Offering and Loan Costs Payment of offering costs and loan origination costs Cash outflow in the form of capital distributions and subsidiary dividends to common shareholders, preferred shareholders and noncontrolling interests. Payments of Subsidiary Dividends Payment of subsidiary dividend Amount of cashless exercise of the company's common stock warrants in noncash investing or financing activities. Cashless Exercise of the Company Common Stock Warrants Cashless exercise of the Company's warrants Amount of common shares and other consideration issued for the purchase of property and equipment in noncash investing or financing activities. Common Shares and Other Consideration Issued for Purchase of Property and Equipment Issuance of the Company's common shares and other consideration for an acquisition Amount of expense or loss included in net income that result in no cash flow, classified as other. Noncash, Other Other Amount of subsidiary shares issued in consideration for debt renegotiation. Issuance of subsidiary Shares in Connection with Debt Renegotiation Issuance of subsidiary shares in connection with debt renegotiation Amount of operating lease right-of-use assets obtained and exchanged for operating lease liabilities. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Operating Lease Right-of-use Assets Obtained and Exchanged for Operating Lease Liabilities Operating lease right-of-use assets obtained and exchanged for operating lease liabilities Amount of gain (loss) on fair value of debt and liability instruments. Gain (Loss) on Fair Value of Debt and Liability Instruments Change in fair value of debt and liability instruments The cash inflow from the sale of assets. Proceeds from Sale of Assets Proceeds from sale of Telavant net assets, net The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period. Repayment of Long Term Debt and Convertible Debt by Subsidiary Repayment of debt by subsidiary The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Non-Cash Acquired In-Process Research and Development Non-cash acquired in-process research and development The cash outflow associated with the warrant redemptions during period of the time. Payment for Warrant Redemptions Payment for redemptions of the Company's warrants Operating Leases [Abstract] Investments Disclosure [Abstract] Investments [Abstract] Unrealized Losses (Gains) on Significant Equity Method Investments [Abstract] Unrealized (Gains) Losses on Significant Equity Method Investments [Abstract] Significant Equity Method Investments [Abstract] Significant Equity Method Investments [Abstract] Certain Balance Sheet Components [Abstract] Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer. Accrued Research and Development Expenses, Current Research and development expenses Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target. Restricted Stock and Performance Stock Units [Member] Restricted Stock Units and Performance Restricted Stock Units (Non-vested) [Member] Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must "earn" part of the purchase price based on the performance of the business. Earn Out Shares Nonvested [Member] Earn-Out Shares (Non-vested) [Member] The other stock based awards and instruments issued related to the awards consisting of stock units. Other Stock Based Awards and Instruments Issued [Member] Other Stock Based Awards and Instruments Issued [Member] Grant date of Capped Value Appreciation Rights (CVARs). March 2020 Capped Value Appreciation Rights Grants [Member] March 2020 CVARs [Member] March 2020 CVAR Grants [Member] Grant date of Capped Value Appreciation Rights (CVARs). November 2021 Capped Value Appreciation Rights Grants [Member] November 2021 CVARs (Non-vested) [Member] November 2021 CVAR Grants [Member] The cash outflow associated with the amount received from entity's raising of capital via private rather than public placement. Exercise of Private Placement Warrants Value Exercise of Private Placement Warrants Performance stock units. Performance Stock Units [Member] Share Based Compensation Arrangements by Share Based Payment Award, Performance Condition During Period [Abstract] PSUs Performance Condition at Tranches [Abstract] The share price of PSUs allocate in each tranche at specified performance period of trading days. Share Based Compensation Arrangement by Share Based Payment Award, Share Price at Tranche Performance Period Share price (in dollars per share) The percentage of PSUs allocated to each tranche during performance period. Share Based Compensation Arrangement by Share Based Payment Award, Percentage of PSUs Allocated Percentage of PSUs Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Share-Based Compensation Award, Tranche Fifth [Member] Fifth Tranche [Member] Sixth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Share-Based Compensation Award, Tranche Sixth [Member] Sixth Tranche [Member] Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period. Share-Based Compensation Award, Tranche Fourth [Member] Fourth Tranche [Member] Represents the Chief Executive Officer and the President and Chief Operating Officer. CEO and COO [Member] 2024 Senior Executive Compensation Program Cash Awards [Abstract] 2024 Senior Executive Compensation Program Cash Awards [Abstract] Cash retention award repayable on the Recoupment Event by the individual. Retention Award Repayable on Recoupment Event Retention award repayable on recoupment event Amount of cash compensation to be recognized over applicable service period. Cash Compensation Amount Cash compensation amount The amount of cash retention awards granted to executives. Cash Retention Awards Cash awards A retention bonus is a targeted one-time payment that is offered as an incentive to keep a key employee on the job. One-Time Cash Retention Awards [Member] One-Time Cash Retention Awards [Member] Capped value appreciation rights to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period. Capped Value Appreciation Rights [Member] CVARs [Member] The Company's stock-based incentive compensation plan. Two015 Stock Based Incentive Compensation Plan [Member] RSL 2015 EIP [Member] The number of equity instruments vested and settled during the period. Equity Instruments Vested and Settled, Shares Equity instruments vested and settled (in shares) Amount of expense incurred for award modification under share-based payment arrangement. Share-Based Payment Arrangement, Award Modification Expense Award modification expense The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, share price hurdle. Share-Based Compensation Arrangement by Share-Based Payment Award, Share Price Hurdle, Weighted Average Price Per Share Hurdle price (in dollars per share) The number of share-based compensation arrangement by share-based payment award equity-based payment instruments, other than options, outstanding shares. Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding Shares Number of shares outstanding (in shares) Number of fully service vested options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Service Vested , Outstanding, Number Number of service-vested shares (in shares)